Telomerase. A target for anticancer therapy

Annals of the New York Academy of Sciences

Volumn 886, Issue , 1999, Pages 1-11

  Lichtsteiner, Serge P ^a   Lebkowski, Jane S ^a   Vasserot, Alain P ^a  

^a GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; TELOMERASE;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL DIVISION; COLON CANCER; CONFERENCE PAPER; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; TELOMERE; UTERUS CANCER;

EID: 0033428321     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09395.x     Document Type: Conference Paper

References (61)

1. 1. Hayflick, L. & P.S. Moorhead. 1961. The serial cultivation of human diploid cell strains. Exp. Cell. Res. 25: 585-621.
2. 2. Harley, C.B. et al. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460.
3. 3. De Lange, T. et al. 1990. Structure and variability of human chromosome ends. Mol. Cell. Biol. 10: 518-527.
4. 4. Hastie, N.D. et al. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346: 866-868.
5. 5. Olovnikov, A.M. 1971. Principle of marginotomy in template synthesis of polynucleotides. Dokl. Akad. Nauk. SSSR 201: 1496-1499.
6. 6. Watson, J.D. 1972. Origin of concatemeric T7 DNA. Nat. New Biol. 239: 197-201.
7. 7. Harley, C.B. 1991. Telomere loss: Mitotic clock or genetic time bomb? Mutat. Res. 256: 271-282.
8. 8. Wright, W.E. et al. 1989. Reversible cellular senescence: Implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol. 9: 3088-3092.
9. 9. Shay, J.W. et al. 1991. A role for both Rb and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196: 33-39.
10. 10. Allsopp, R.C. et al. 1992. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. USA 89: 10114-10118.
11. 11. Counter, C.M. et al. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11: 1921-1929.
12. 12. Kim, N.W. et al. 1994. Specific association of human telomerase activity with immortal cell lines and cancer. Science 266: 2011-2015.
13. 13. Wright, W.E. et al. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18: 173-179.
14. 14. Broccoli, D. et al. 1995. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA 92: 9082-9086.
15. 15. Counter, C.M. et al. 1995. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85: 2315-2320.
16. 16. Taylor, R.S. et al. 1996. Detection of telomerase activity in malignant and nonmalignant skin conditions. J. Invest. Dermatol. 106: 759-765.
17. 17. Hiyama, E. et al. 1996. Telomerase activity in human intestine. Int. J. Oncol. 9: 453-458.
18. 18. Bodnar, A.G. et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.
19. 19. Nakamura, T.M. et al. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
20. 20. Meyerson, M. et al. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
21. 21. Kilian, A. et al. 1997. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6: 2011-2019.
22. th Annual Meeting of the American Society of Hematology (Miami, FL). American Society of Hematology. Westerville, OH.
23. 23. Shay, J.W. & S. Bacchetti. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33: 787-791.
24. 24. Sharma, S. et al. 1997. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol. 8: 1063-1074.
25. 25. Feng, J. et al. 1995. The RNA component of human telomerase. Science 269: 1236-1241.
26. 26. Mata J.E. et al. 1997. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharmacol. 144: 189-197.
27. 27. Kondo, S. et al. 1998. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16: 3323-3330.
28. 28. Kondo, S. et al. 1998. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12: 801-811.
29. 29. Weinrich, S.L. et al. 1997. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet. 17: 498-502.
30. 30. Dickinson, L.A. et al. 1998. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Natl. Acad. Sci. USA 95: 12890-12895.
31. 31. Werstuck, G. & M.R. Green. 1998. Controlling gene expression in living cells through small molecule-RNA interactions. Science 282: 296-298.
32. 32. Wright, W.E. et al. 1996. Experimental elongation of telomeres in immortal human cells extends the lifespan of immortal x normal cell hybrids. EMBO J. 15: 1734-1741.
33. 33. Ohmura, H. et al. 1995. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jpn. J. Cancer Res. 86: 899-904.
34. 34. Sharma, H.W. et al. 1995. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Acad. Sci. USA 92: 12343-12346.
35. 35. Bestilny, L.J. et al. 1996. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res. 56: 3796-3802.
36. 36. Savoysky, E. et al. 1996. Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. Biochem. Biophys. Res. Commun. 226: 329-334.
37. 37. Xu, D. et al. 1996. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 10: 1354-1357.
38. 38. Pitts, A.E. & D.R. Corey. 1998. Inhibition of human telomerase by 2'-O-methyl-RNA. Proc. Natl. Acad. Sci. USA 95: 11549-11554.
39. 39. Norton, J.C. et al. 1996. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14: 615-619.
40. 40. Strahl, C. & E.H. Blackburn. 1996. Effect of reserve transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16: 53-65.
41. 41. Yegorov Y.E. et al. 1996. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett. 389: 115-118.
42. 42. Melana, S.M. et al. 1998. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin Cancer Res. 4: 693-696.
43. 43. Naasani, I. et al. 1998. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 249: 391-396.
44. 44. Fletcher, T.M. et al. 1996. Human telomerase inhibition by 7-deaza-2'-deoxypurine nucleoside triphosphates. Biochemistry 35: 15611-15617.
45. 45. Wheelhouse, R.T. et al. 1998. Cationic porphyrins as telomerase inhibitors: The interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J. Am. Chem. Soc. 120: 3261-3262.
46. 46. Fedoroff, O.Y. et al. 1998. NMR-based model of a telomerase inhibiting compound bound to G-quadruplex DNA. Biochemistry 37: 12367-12374.
47. 47. Sun, D. et al. 1997. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40: 2113-2116.
48. 48. Perry, P.J. et al. 1998. 1,4-and 2,6-disubstituted amidoanthracene-9, 10-dione derivatives as inhibitors of human telomerase. J. Med. Chem. 41: 3253-3260.
49. 49. Bare, L.A. et al. 1998. Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay. Drug Dev. Res. 43: 109-116.
50. 50. Blackburn, E.H. & C.W. Greider, Eds. 1995. Telomeres. Cold Spring Harbor Press, New York.
51. WAFI gene expression. Mol. Carcinog. 21: 26-36.
52. 52. Vignoli, M. et al. 1998. Impaired telomerase activity in uninfected haematopoietic progenitors in HIV-1-infected patients. AIDS 12: 999-1005.
53. 53. Zhu, X. et al. 1996. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095.
54. 54. Xu, H.J. et al. 1997. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15: 2589-2596.
55. 55. Luo, Y. et al. 1995. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cipl. Nature 375: 159-161.
56. 56. Franzese, O. et al. 1998. Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Res. 8: 323-328.
57. 57. Robinson, M. et al. 1998. hTERT inhibition in human immortal cells. Collected Abstracts of the Geron Symposium No. 2: Telomerase and Telomere Dynamics in Cancer and Aging (Maui, HI). Geron Corporation. Menlo Park, CA.
58. 58. Li, H. et al. 1997. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem. 272: 16729-16732.
59. 59. Ku, W.C. et al. 1997. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. 241: 730-736.
60. 60. Kanazawa, Y. et al. 1996. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225: 570-576.
61. 61. Wan, M.S. et al. 1998. Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8: 309-317.